REFERENCES

- Mikhael HJC (2007) Bortezomib: proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies. Letters in Drug Design & Discovery 4: 82-86.

- Richardson PG, Mitsiades C, Schlossman R (2008) Bortezomib in the frontline treatment of multiple myeloma. Expert Review of Anticancer Therapy 8:1053-1072.
- Richardson PG, Hideshima T, Mitsiades C, Anderson K (2004) Proteasome inhibition in hematologic malignancies. Annals of Medicine 4: 304-314.
- Smith MB, March J (2007) March's Advanced Organic Chemistry. John Wiley & Sons, Hoboken, NJ, USA, 6th edition.
- Pitt B, Remme W, Zannad F (2003) Bortezomib Post Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. ACC Current Journal Review 12: 57.
- Burgess E, Niegowksa J, Tan KW, Kipnes MS, Roniker B, et al. (2002) Bortezomib 016 Investigators. American Journal of Hypertension 15: A23, A57-A58.
- Olayioye M, Beuvink I, Horsch K, Daly J, Hynes N (1999) ErbB receptorinduced activation of STAT transcription factors is mediated by Src kinases. J Biol Chem 274.
- Wiley H S, Burke P (2001) Regulation of receptor tyrosine kinase signaling by endocytic trafficking. Traffic 2: 12-18.
- Bruce A Pearlman, Amphlett G Padilla, John T Hach, Jeffrey L Havens, Muniraj D, et al. (2006) New Approach to the Furan Degradation Problem Involving Ozonolysis of the *trans*-Enedione and Its Use in a Cost-Effective Synthesis of Bortezomib Chemical Research and Development. Pfizer, Incorporated, Kalamazoo, Michigan 49001-0102 Org Lett 8: 2111-2113.
- Ji Y Zhang, Douglas M Fast, Alan P Breau (2003) Journal of Chromatography B 787: 333-344.

- Rane VP, Patil kr, Sangshetti NJ, Yeole RD, Shinde DB (2009) Stabilityindicating RP-HPLC method for analysis of bortezomib in the bulk drug and in a pharmaceutical dosage form 21: 619-629.
- Scientific discussion on Bortezomib 1st may 2004 EMEA.
- Assessment Report for Velcade, London, 18 August 2008. EMEA/CHMP/441020/2008
- Bortezomib (Velcade) pack insert.
- Adams J, Kauffman M (2004). "Development of the Proteasome Inhibitor Velcade (Bortezomib)". *Cancer Invest* 22 (2): 304–11. doi:10.1081/CNV-120030218. PMID 15199612.
- Stephen R.Byrn et al (2011). "Analysis of two commercially available bortezomib products: differences in assay of active agent and impurity profile". *AAPS PharmSciTech* (April 1)
- Bakshi Singh MS et al (2002) Development of validated stability indicating assay methods-critical Review. J Pharm Biomed Anal 28: 1011-1040.
- Bardin C et al (2013). “Guidelines for the practical stability studies of anticancer drugs a European consensus conference”
- Arun Kumar Kuna at al (2012). “Analytical Method Development And Validation For The Estimation of Bortezomib in Parenteral Formulation by RP-HPLC Method” J Pharmacy Research, 5(6), 3193-3195
- Rambabu C. et al (2011). “Estimation of Bortezomib in Bulk and its Pharmaceutical Dosage Forms by Using a Novel Validated Accurate Reverse Phase High Performance Liquid Chromatography” International Journal of Pharmacy and Pharmaceutical Sciences, Vol 3, Issue3
- J Scott Daniels et al (2005) J. of drugmetobolism and Disproposition, vol: 33, No: 6, 771-777.
- Gerald H. Manorek et al(2009), Alison K. Holzer and Dr.Stephen B. Howell Clin. Cancer Res. 15: 553-560
- Jeffrey S et al (2008), Journal of chromatography, vol: 871, issues 1, 15-21.
- Cecilia Ceresa et al (2009), J. Peters. Mol Cancer theremay, 8, 1026.
- Kasa Srinivasulu et al, “Development and validation of stability indicating LC method for the assay and related substances determination of a proteasome inhibitor Bortezomib”

- Venkataramanna M. et al (2012). “A Validated Stability-Indicating UF LC Method for Bortezomib in the Presence of Degradation Products and its Process-Related Impurities” J Chromatograph Separat Techniq, 3:1
- Rane VP. et al(2009) “Stability indicating RP-HPLC method for analysis of Bortezomib in the bulk drug and in a pharmaceutical dosage form” 21: 619-629.
- ICH Q2 (R1) (2005) Validation of analytical procedures: Text and methodology.
- ICH, Photo stability testing of new drug substances and products Q1B.
- ICH Guidelines on validation of analytical Procedures definitions and terminology.
- Burgess E, et al. (2002) Bortezomib 016 Investigators. American Journal of Hypertension 15: A23, A57-A58.
- Validation of compendial methods (2013) The United States Pharmacopeia. 35th edn, USP35.
- ICH Stability Testing of New Drug Substances and Products Q1A (R2) (2003) International Conference on Harmonization, IFPMA, Geneva.